-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Big Cypress Acquisition (OTCMKTS:BCYP) Vs. Orchard Therapeutics (NASDAQ:ORTX) Head-To-Head Contrast
Big Cypress Acquisition (OTCMKTS:BCYP) Vs. Orchard Therapeutics (NASDAQ:ORTX) Head-To-Head Contrast
Big Cypress Acquisition (OTCMKTS:BCYP – Get Rating) and Orchard Therapeutics (NASDAQ:ORTX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Profitability
This table compares Big Cypress Acquisition and Orchard Therapeutics' net margins, return on equity and return on assets.
Get Big Cypress Acquisition alerts:| Net Margins | Return on Equity | Return on Assets | |
| Big Cypress Acquisition | N/A | N/A | N/A |
| Orchard Therapeutics | -1,452.46% | -86.92% | -54.69% |
Valuation & Earnings
This table compares Big Cypress Acquisition and Orchard Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Big Cypress Acquisition | N/A | N/A | -$10,000.00 | N/A | N/A |
| Orchard Therapeutics | $1.67 million | 45.67 | -$144.58 million | ($1.33) | -0.45 |
Institutional & Insider Ownership
60.2% of Big Cypress Acquisition shares are owned by institutional investors. Comparatively, 56.5% of Orchard Therapeutics shares are owned by institutional investors. 3.3% of Orchard Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations for Big Cypress Acquisition and Orchard Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Big Cypress Acquisition | 0 | 0 | 2 | 0 | 3.00 |
| Orchard Therapeutics | 1 | 2 | 3 | 0 | 2.33 |
Big Cypress Acquisition currently has a consensus price target of $17.25, indicating a potential upside of 104.38%. Orchard Therapeutics has a consensus price target of $7.75, indicating a potential upside of 1,185.03%. Given Orchard Therapeutics' higher possible upside, analysts plainly believe Orchard Therapeutics is more favorable than Big Cypress Acquisition.
Summary
Big Cypress Acquisition beats Orchard Therapeutics on 6 of the 10 factors compared between the two stocks.
About Big Cypress Acquisition
(Get Rating)
Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.
About Orchard Therapeutics
(Get Rating)
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Big Cypress Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Big Cypress Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Big Cypress Acquisition (OTCMKTS:BCYP – Get Rating) and Orchard Therapeutics (NASDAQ:ORTX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
大柏收购(OTCMKTS：BCYP-GET Rating)和果园治疗(纳斯达克：ORTX-GET Rating)都是小盘医疗公司，但哪只是优势股？我们将根据两家公司的收益、估值、盈利能力、风险、分析师建议、股息和机构持股等方面的实力进行比较。
Profitability
盈利能力
This table compares Big Cypress Acquisition and Orchard Therapeutics' net margins, return on equity and return on assets.
此表比较了Big Cypress收购和Orchard Treeutics的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Big Cypress Acquisition | N/A | N/A | N/A |
| Orchard Therapeutics | -1,452.46% | -86.92% | -54.69% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 大柏树收购 | 不适用 | 不适用 | 不适用 |
| 果园治疗学 | -1,452.46% | -86.92% | -54.69% |
Valuation & Earnings
估值与收益
This table compares Big Cypress Acquisition and Orchard Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
此表比较了Big Cypress收购和Orchard Treeutics的营收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Big Cypress Acquisition | N/A | N/A | -$10,000.00 | N/A | N/A |
| Orchard Therapeutics | $1.67 million | 45.67 | -$144.58 million | ($1.33) | -0.45 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 大柏树收购 | 不适用 | 不适用 | -$10,000.00 | 不适用 | 不适用 |
| 果园治疗学 | 167万美元 | 45.67 | -1.4458亿美元 | ($1.33) | -0.45 |
Institutional & Insider Ownership
机构与内部人持股
60.2% of Big Cypress Acquisition shares are owned by institutional investors. Comparatively, 56.5% of Orchard Therapeutics shares are owned by institutional investors. 3.3% of Orchard Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
60.2%的大柏树收购股份由机构投资者持有。相比之下，Orchard Treeutics 56.5%的股份由机构投资者持有。Orchard Treeutics 3.3%的股份由内部人士持有。强大的机构持股表明，大型基金管理公司、捐赠基金和对冲基金相信，一家公司有望实现长期增长。
Analyst Recommendations
分析师建议
This is a summary of current recommendations for Big Cypress Acquisition and Orchard Therapeutics, as reported by MarketBeat.
这是MarketBeat报道的对Big Cypress收购和Orchard Treeutics的当前建议的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Big Cypress Acquisition | 0 | 0 | 2 | 0 | 3.00 |
| Orchard Therapeutics | 1 | 2 | 3 | 0 | 2.33 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 大柏树收购 | 0 | 0 | 2 | 0 | 3.00 |
| 果园治疗学 | 1 | 2 | 3 | 0 | 2.33 |
Big Cypress Acquisition currently has a consensus price target of $17.25, indicating a potential upside of 104.38%. Orchard Therapeutics has a consensus price target of $7.75, indicating a potential upside of 1,185.03%. Given Orchard Therapeutics' higher possible upside, analysts plainly believe Orchard Therapeutics is more favorable than Big Cypress Acquisition.
大柏树收购目前的一致目标价为17.25美元，表明潜在上行空间为104.38%。Orchard Treateutics的共识目标价为7.75美元，表明潜在涨幅为1185.03%。考虑到Orchard Treeutics的更高可能上行空间，分析师们显然认为Orchard Treeutics比Big Cypress收购更有利。
Summary
摘要
Big Cypress Acquisition beats Orchard Therapeutics on 6 of the 10 factors compared between the two stocks.
与两只股票相比，大柏树收购在10个因素中有6个击败了Orchard Treeutics。
About Big Cypress Acquisition
关于大柏树的收购
(Get Rating)
(获取评级)
Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.
大柏树收购公司没有重要的业务。公司拟通过合并、换股、购股、重组或类似的业务合并等方式收购资产和业务。它主要集中在生命科学领域。该公司成立于2020年，总部设在佛罗里达州迈阿密海滩。
About Orchard Therapeutics
关于果园治疗公司
(Get Rating)
(获取评级)
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Orchard Treateutics公司是一家生物制药公司，在英国、欧盟和美国开发针对严重和危及生命的罕见疾病的基因疗法。该公司的基因疗法寻求将患者的造血干细胞转化为基因修饰的细胞药物产品，通过单一给药来治疗患者的疾病。它提供Strimvelis，一种基于伽玛逆转录病毒的产品，用于治疗腺苷脱氨酶-严重联合免疫缺陷(ADA-SCID)。该公司的临床开发产品包括用于治疗ADA-SCID的OTL-101；用于治疗异色性脑白质营养不良的OTL-200；用于治疗Wiskott-Aldrich综合征的OTL-103；用于X连锁慢性肉芽肿疾病的OTL-102；以及用于输血依赖型β-地中海贫血的OTL-300。其临床前计划包括针对I型粘多糖病的OTL-203、针对MPS-IIIA型的OTL-201以及针对IIIB型粘多糖病的OTL-202。它与Pharming Group N.V.就OTL-105的研究、开发、制造和商业化达成了战略合作协议。OTL-105是一种用于治疗遗传性血管性水肿的体外自体造血干细胞基因疗法。该公司前身为Orchard Rx Limited。Orchard Treeutics plc成立于2015年，总部设在英国伦敦。
Receive News & Ratings for Big Cypress Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Big Cypress Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
接受《大柏树收购日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Big Cypress收购和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧